Abstract:The aging of the population has led to a significant increase in the incidence and prevalence rate of dementia, especially Alzheimer's disease (AD). Positron emission tomography (PET) is one of the most advanced molecular imaging diagnostic techniques in recent years. In the field of dementia, based on neuropathology, radio-labeled molecular probes of amyloid and tau tracer can objectively detect the distribution of abnormal protein deposition in the brain, which can be widely used in the early diagnosis and differential diagnosis of AD, disease progression and prognosis assessment. This paper focuses on the development and clinical research status of molecular probes for amyloid and tau protein.
